Quick answer
What is CJC-1295 with DAC, and what makes it different from other GHRH analogs? CJC-1295 with DAC is a synthetic analog of growth-hormone-releasing hormone built on the first 29 residues of the native hormone, with four amino acid substitutions that protect the backbone from peptidases and one added C-terminal lysine carrying a maleimide-based drug affinity complex (DAC). The maleimide reacts with the free thiol of cysteine-34 on serum albumin, so in biological systems the peptide travels largely as an albumin conjugate. That is the entire difference: DAC changes how long the molecule is present, not which receptor it activates. This article explains the chemistry step by step, with a bench-focused emphasis on what thiol reactivity means for reconstitution, additives and analysis. V8 does not stock the DAC form; the closely related CJC-1295 (No DAC) is listed for comparison work. For laboratory research use only; not for human consumption.
Most explanations of CJC-1295 with DAC stop at the sentence that the DAC makes it last longer. That is correct but leaves out what a researcher handling the compound needs to know: a reactive group sits at the C-terminus, and a reactive group has consequences for solvents, additives, storage and analytical readouts. This guide follows the chemistry from the native hormone to the albumin conjugate and then to the bench. It is a companion to, and does not repeat, the compound reference in the CJC-1295 with DAC research overview; the side-by-side comparison with the unmodified form is in CJC-1295 DAC vs no DAC.
Starting point: native GHRH and why it is short-lived
Growth-hormone-releasing hormone was characterized as a 44-residue peptide from a human pancreatic tumor by Rivier and colleagues in 1982. The first 29 residues retain full receptor-activating potency, which is why GHRH(1-29) became the scaffold for analogs. The unmodified fragment is cleared quickly. Frohman and colleagues showed that dipeptidyl peptidase IV and trypsin-like enzymes degrade human GHRH in plasma, and that cleavage at the N-terminal Ala2 produces an inactive fragment, so the half-life of the native sequence in plasma is measured in minutes. Any strategy that extends the useful life of a GHRH analog has to deal with that rapid enzymatic cleavage and with renal clearance of a small peptide.
Two modifications, two jobs
| Modification | Where | What it addresses |
|---|---|---|
| Four residue substitutions in the GHRH(1-29) sequence | Along the backbone, including the N-terminal region | Resistance to peptidase cleavage, especially the DPP-IV site at position 2 |
| Added C-terminal lysine with a maleimidopropionyl group (the DAC) | C-terminus | Covalent attachment to serum albumin, which turns over slowly and is not filtered by the kidney |
Together they make a peptide that resists enzymatic cleavage and, once bound to albumin, avoids filtration. Jetté and colleagues studied bioconjugates of human GHRH(1-29) with albumin and reported that the conjugates activated the GRF receptor on the anterior pituitary in rats and identified CJC-1295 as a long-lasting analog, which established the principle that attaching an albumin carrier need not abolish receptor activity. The receptor-facing portion of the molecule is shared with the no-DAC analog; the pharmacology of the receptor is the same and is covered in the CJC-1295 (No DAC) research overview.
The maleimide-thiol reaction
A maleimide is an electron-poor alkene that reacts with a thiol (sulfhydryl) group by a Michael addition to form a stable thioether bond. In a biological setting the available thiol is the free cysteine-34 of albumin, which is the most abundant free thiol in plasma. The bond is covalent and, in practice, not readily reversed under physiological conditions, which is why the half-life of the albumin conjugate is set by albumin turnover and not by the peptide.
The same reactivity explains why the lyophilized material needs care before it meets albumin. A maleimide will react with any accessible thiol, not only the albumin one, and it can also be hydrolyzed by water, especially at higher pH, to a ring-opened form that no longer reacts. Both events consume the reactive group. Trivedi and colleagues reviewed the role of thiols and disulfides in protein stability, which is relevant to understanding what other reagents in a solution can interact with a thiol-reactive molecule.
| Condition | Effect on a maleimide group | Bench consequence |
|---|---|---|
| Free thiols in the solution (DTT, β-mercaptoethanol, cysteine, glutathione) | Reacts with the maleimide and caps it | Do not add thiol reagents to the stock |
| Neutral to basic pH | Faster hydrolysis to the ring-opened, unreactive form | Keep stock near neutral or slightly acidic and short-lived |
| Warm storage | Accelerates both hydrolysis and other degradation | Keep cold and dry; avoid long room-temperature holds |
| Primary amines at high pH | Can compete with thiols at elevated pH | Avoid amine-rich buffers at high pH |
| Intact lyophilized cake, dry and cold | Group is protected from water | Store sealed and protected from moisture and light |
What follows for reconstitution and additives
- Choose the diluent for what it lacks. Bacteriostatic water contains water and benzyl alcohol and no thiols, so it adds no competing nucleophile; see bacteriostatic water explained.
- Avoid reducing agents and any additive with a free sulfhydryl group.
- Calculate stock concentration by formula. Concentration equals vial mass divided by diluent volume; the reconstitution calculator performs the arithmetic and V8 publishes no fixed per-compound volume table.
- Keep holds short. A solution is the state in which the maleimide can hydrolyze, so prepare what the experiment needs and retire the rest.
- Use low-binding labware. Basic peptides adsorb to glass and some plastics, documented for cationic peptides by Kristensen and colleagues.
The general method is in how to reconstitute a lyophilized peptide. Peptide stability in solution is reviewed by Manning and colleagues (2010), and the properties of the lyophilized state by Carpenter and colleagues (1997).
How the conjugation changes experimental design
For a lab studying the GHRH receptor pathway, the DAC form and the no-DAC form answer different questions. The same receptor and downstream cascade, from Gs-coupled receptor activation through cAMP to growth hormone synthesis and release, are engaged in both. What differs is the time profile of receptor exposure in an animal or in a culture system that contains albumin.
| Question being asked | Form that matches | Reason |
|---|---|---|
| Response to brief, pulsatile receptor stimulation | Unmodified analog (No DAC) | Cleared within minutes, so exposure is short |
| Response to sustained receptor availability | DAC form | Albumin conjugate persists for days in animal models |
| Receptor binding or signaling in a short in vitro assay | Either; check the medium | Albumin in the medium can conjugate the DAC form |
| Chemistry of GHRH(1-29) alone | No DAC | No reactive group to account for |
Culture media containing serum or albumin will react with a DAC compound, which can change the effective free concentration of the peptide during an experiment. A lab that wants to study the peptide itself should state the medium composition and record how long the compound was in contact with albumin before measurement. The wider context is in CJC-1295 DAC vs no DAC and the broader CJC-1295 vs sermorelin comparison.
Verifying a DAC compound analytically
A maleimide-bearing peptide changes what an analytical certificate must show. Purity by HPLC tells how much of the signal is the main peak, but a hydrolyzed maleimide elutes close to the intact form and has a mass higher by 18 Da, the mass of one water molecule. The mass of the DAC form is about 3,647 Da compared with about 3,368 Da for the no-DAC analog, so a mass-based identity test distinguishes the two clearly and also reveals the ring-opened species. How these methods complement each other is explained in understanding HPLC purity and how to read a COA. Because V8 does not list a DAC product, no V8 certificate exists for it; the principle applies to any supplier's certificate, and the certificates V8 does publish are collected on the COA page.
What is and is not in the primary literature
The literature on albumin-conjugated GHRH analogs spans receptor-activation work in rats such as that of Jetté and colleagues, enzymatic-stability studies such as those of Frohman and colleagues, and animal-model pharmacology. These are research findings on peptide behavior in model systems. They are not guidance for any use outside the laboratory, and this article makes no claim about them. Readers interested in the compound class can also consult the CJC-1295 (No DAC) purity testing article for analytical details that carry over, and browse the shop page for the related compounds V8 lists.
Related reading: CJC-1295 DAC and Ipamorelin Stack: GH-Axis Research.
References
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. doi:10.1172/JCI114049
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides on protein stability. Curr Protein Pept Sci. 2009;10(6):614-625. doi:10.2174/138920309789630534
- Kristensen K, Henriksen JR, Andresen TL. Adsorption of cationic peptides to solid surfaces of glass and plastic. PLoS One. 2015;10(5):e0122419. doi:10.1371/journal.pone.0122419
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969-975. doi:10.1023/A:1012180707283
Frequently Asked Questions
What does DAC stand for in CJC-1295 with DAC?
DAC stands for drug affinity complex, a maleimide-bearing group attached through an added C-terminal lysine. It bonds covalently to the free thiol of cysteine-34 on serum albumin.
Does DAC change which receptor the peptide activates?
No. The receptor-facing portion is the same as in the no-DAC analog, so the GHRH receptor pharmacology is unchanged. DAC changes how long the molecule is available.
Why should thiol-containing additives be avoided?
A maleimide reacts with free thiols such as DTT, cysteine or glutathione, which would cap the reactive group before it reaches albumin.
Why does pH matter for a maleimide?
At neutral to basic pH water can open the maleimide ring, producing a form that no longer reacts with thiols. Short holds near neutral or slightly acidic pH limit this.
Does V8 sell CJC-1295 with DAC?
No. V8 stocks CJC-1295 (No DAC), which is useful as the unmodified comparison compound.
How can a DAC peptide be told apart from the no-DAC form analytically?
By mass: the DAC form is about 3,647 Da and the no-DAC form about 3,368 Da, so a mass-based identity test separates them and also reveals a hydrolyzed form 18 Da heavier.
Why does culture medium composition matter?
Serum or albumin in the medium contains free thiol groups that will conjugate a DAC compound, changing the free peptide concentration during the experiment.
What diluent is suitable for reconstitution?
One without thiols or strong nucleophiles. Bacteriostatic water contains only water and benzyl alcohol, so it adds no competing reactive group, but the assay should be checked for benzyl alcohol tolerance.
Is CJC-1295 with DAC sold for consumption by people or animals?
No. The compound is discussed here as a laboratory research subject only, and V8 products are sold for laboratory research use only.
